Familial Combined Hyperlipidemia: Myth or Reality?

Area of Science:

• Genetics
• Metabolic Disorders
• Cardiovascular Disease

Background:

• Familial combined hyperlipidemia (FCHL) was initially described in 1973 as an autosomal dominant disorder associated with premature myocardial infarction.
• The definition and genetic basis of FCHL have been subjects of ongoing research and debate.

Purpose of the Study:

• To provide a historical overview of the metabolic and genetic abnormalities characterizing FCHL.
• To integrate historical findings with recent genetic and population studies to propose a new pathophysiological concept of FCHL.
• To offer practical guidance for managing patients with an FCHL phenotype.

Main Methods:

• Review of historical literature on FCHL.
• Analysis of quantitative trait linkage studies.
• Inclusion of data from genome-wide association studies (GWAS) and next-generation sequencing (NGS).
• Integration of findings from recent population-based and genetic studies.

Main Results:

• FCHL is confirmed as a polygenic disorder, with multiple associated gene variants, primarily affecting triglyceride levels.
• The identified gene variants are not unique to FCHL.
• The multiple-type hyperlipidemia phenotype is not exclusively confined to FCHL.
• A new pathophysiological model for FCHL has been developed based on integrated findings.

Conclusions:

• FCHL is a complex polygenic condition, challenging the initial autosomal dominant model.
• The understanding of FCHL requires integration of historical metabolic data with modern genetic insights.
• The proposed model offers a framework for clinical management of individuals presenting with FCHL phenotypes.